Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EU Issues Plans For Significant Changes To Manufacturing Standards For Sterile Medicines

Executive Summary

Long-awaited plans to change the EU guideline on manufacturing standards for sterile medicinal products are out for consultation. The proposals were drafted in cooperation with the World Health Organization and the international pharmaceutical inspectorate group, PIC/S, to ensure global alignment of standards.


Related Content

Timeline For EU GMP Annex 1 Revision Remains Unclear
EU GMP Annex 1 Would Give Microbiologists A Greater Role In Sterility Assurance, Rapporteur Says
EMA Aims To Carry On With EU GMP Annex 1 Revision Despite Brexit-Related Staff Departures
Industry Consortium Developing Best Practices For Meeting Proposed EU GMP PUPSIT Requirement
Industry Groups Raise Concerns About Proposed EU GMP Annex 1 Revisions
Significant Revisions To Annex 1 Cleanroom Standard Soon To Be Released
EMA, PIC/S to Revise Annex 1 Sterile Manufacturing Guidelines; PDA Offers Detailed Advice
PIC/S adopts technical interpretation of revised GMP requirements for sterile products





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts